Clinical Trials Browser

Phase 1 × OTHER × Brentuximab Vedotin × Clear all

NCT05414500 2025-08-08

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Phase 1 Recruiting

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT02616965 2025-04-04

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Phase 1 Completed

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT03013933 2024-02-22

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

Hodgkin Disease

NCT03302728 2022-05-19

EpiBrentlen

Phase 1 Completed

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02086604 2022-02-17

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT01830777 2020-04-14

Brentuximab Vedotin + Re-induction Chemotherapy for AML

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02254239 2019-12-12

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Terminated

Hodgkin Disease

NCT02822586 2019-08-30

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Phase 1 Completed

Mycosis Fungoides, Sezary Syndrome

NCT03373305 2019-04-30

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Phase 1 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT01700751 2019-04-16

Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02780011 2018-07-27

AD3LE

Phase 1 Withdrawn

Recurrence

NCT02280993 2018-03-13

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Phase 1 Unknown

Hodgkin Disease, Recurrence

NCT03205891 2018-01-17

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Phase 1 Withdrawn

Lymphoma, Large-Cell, Anaplastic